Skip to main content
$30.92 -$0.60 (-1.9%)

04:00 PM EST on 02/03/23

Cassava Sciences, Inc. (NASDAQ:SAVA)

CAPS Rating: 1 out of 5

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

Current Price $30.92 Mkt Cap $1.3B
Open $30.96 P/E Ratio 0.00
Prev. Close $30.92 Div. (Yield) $0.00 (0.0%)
Daily Range $30.46 - $32.38 Volume 1,082,955
52-Wk Range $13.84 - $62.49 Avg. Daily Vol. 1,707,251

Caps

How do you think NASDAQ:SAVA will perform against the market?

Add Stock to CAPS Watchlist

All Players

195 Outperform
33 Underperform
 

All-Star Players

30 Outperform
10 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:SAVA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFjimhalley (< 20)
Submitted July 12, 2021

The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.

wpshil78 (33.57)
Submitted November 08, 2022

It has 1 drug candidate for Alzheimer's that is a long-shot for approval. Heavily-shorted stock.

Recent Community Commentary

Read the most recent pitches from players about SAVA.

Recs

1
Member Avatar wpshil78 (33.57) Submitted: 11/8/2022 3:44:00 PM : Underperform Start Price: $34.83 NASDAQ:SAVA Score: +19.02

It has 1 drug candidate for Alzheimer's that is a long-shot for approval. Heavily-shorted stock.

Recs

1
Member Avatar TMFjimhalley (< 20) Submitted: 7/12/2021 6:46:55 PM : Outperform Start Price: $100.15 NASDAQ:SAVA Score: -63.65

The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.

Recs

1
Member Avatar kfox (< 20) Submitted: 2/2/2021 4:28:30 PM : Outperform Start Price: $33.39 NASDAQ:SAVA Score: -15.48

They just released information of a trial they did with their treatment for Alzheimer's Disease. The results of the trial were positive, patients had an improvement in cognition and behavior. the name of the treatment/drug is Simufilam.

Leaderboard

Find the members with the highest scoring picks in SAVA.

Score Leader

medeaschild

medeaschild (79.11) Score: +3,871.78

The Score Leader is the player with the highest score across all their picks in SAVA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
medeaschild 79.11 12/26/2018 Outperform NS $0.76 +3,946.27% +74.49% +3,871.78 0 Comment
foolrrrrrrrrrr 40.85 11/13/2008 Underperform 1Y $37.61 -18.15% +399.88% +418.03 0 Comment
marcet 75.10 3/2/2009 Underperform 3W $18.82 +63.51% +477.83% +414.32 0 Comment
SmallCapSurfer2 67.14 10/13/2016 Outperform 3M $5.32 +478.57% +94.07% +384.50 0 Comment
Dennyf10 65.70 10/16/2008 6/22/2009 Underperform 1Y $35.72 -13.84% +361.46% +375.30 0 Comment
hackerbobZ < 20 3/23/2009 Underperform 5Y $17.65 +74.37% +428.37% +354.01 0 Comment
deemonfather42 < 20 7/6/2009 Underperform 3W $22.42 +37.28% +362.62% +325.34 0 Comment
capptten < 20 12/1/2020 Outperform 3M $7.66 +301.83% +12.63% +289.20 1 Comment
kozmo66 < 20 9/22/2008 Underperform 3M $38.69 -20.45% +239.06% +259.51 0 Comment
MARTIJN76 93.11 10/19/2006 Underperform 3M $35.60 -13.54% +220.53% +234.07 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SAVA.